Former Australian Member of Parliament Says Pfizer and AstraZeneca Paid Lobbyists to Direct Australia’s Leaders to Push Vaccine Mandates

Former Australian Member of Parliament Says Pfizer and AstraZeneca Paid Lobbyists to Direct Australia’s Leaders to Push Vaccine Mandates

Clive Palmer

A former Australian member of Parliament came out and said Pfizer and AstraZeneca are paying lobbyists to direct Australia’s leaders to push vaccine mandates.

Clive Palmer, leader of the United Australia Party claimed ousted New South Wales Premier Gladys Berejiklian was told she wouldn’t be charged in a corruption probe if she imposed a vaccine mandate.

Palmer made these statements a couple weeks ago but it has garnered a lot of attention this weekend after Berejiklian resigned in disgrace following a corruption probe.

Two weeks ago, Palmer said Pfizer and AstraZeneca were paying lobbyists tens of millions of dollars to direct Australia’s liberal leaders to push the double jab.

According to Palmer, Berejiklian, who was under a corruption probe by the ICAC at the time, was told if she imposed strict lockdowns and vaccine mandates, she wouldn’t be charged.

Shortly before Berejiklian resigned, she told Sydney residents that if they don’t take the Covid jab, they face total social isolation indefinitely after the stay-at-home order ends in December.

Berejiklian made history for overseeing one of the most fascistic regimes in modern history like nothing we have witnessed in the Western world.

It appears she was bowing to Big Pharma lobbyists and special interest groups once again proving Covid mandates have NOTHING to do with science or saving lives.

Clive Palmer told reporters of Berejiklian: “The only way she gets out of the inquiry is if she pushes the double jab.”

A lefty reporter pushed back on Clive Palmer: “You think the premier of New South Wales is trying to destroy businesses?”

“I do,” Palmer replied. “She’s being directed by lobbyists in Sydney, who is being paid by AstraZeneca and by Pfizer tens of millions of dollars to get these policies through, to make sure the vaccines get pushed…that’s my personal knowledge and I’m happy to make a statement here, to police, to anyone.”

BILL GATES ADMITS THAT COVID-19 JAB DOESN’T PREVENT TRANSMISSION

Ever since the “jab” became available in the government’s COVID arsenal, there’s been discussion and argument about whether it helps. Many people …

BILL GATES ADMITS THAT COVID-19 JAB DOESN’T PREVENT TRANSMISSION

Compliments of Julio Cahn from thepatriot.com and WND

Ever since the “jab” became available in the government’s COVID arsenal, there’s been discussion and argument about whether it helps.​

Many people have developed so-called “breakthrough” cases of COVID-19, that is, they got the virus even though they’d been vaccinated. Others say the shots absolutely prevent damage.

Now Bill Gates, a longtime vaccine activist, although he’s no doctor, has openly admitted the mRNA shots being used today don’t help prevent transmission.

He was interviewed recently on the topic of COVID and vaccines, and said, “Economic damage, the deaths, it’s been completely horrific and I would expect that will lead the R and D (research and development) budgets to be focused on things we didn’t have today.”

He continued, “You know, we didn’t have vaccines that blocked transmission. We got vaccines that help you with your health, but they only slightly reduce transmission.”

A commentary at Rebel News blog pointed out Gates said the nation needs “a new way of doing things.”

The commentary said, “Gates has helped to fund and promote vaccine passports globally. He has promoted and defended authoritarian lockdowns. He has aggressively pushed for these vaccines to be injected into every man, woman and child. But now, Gates acknowledges, and publicly states, that the current COVID shots are not effective at stopping transmission.”

Another blog posting noted that Twitter, ironically, fact-checked the statement as “misleading,” but what was significant about that was that the statement was allowed to remain on social media.
Most of those giant corporations are censoring anything that diverges from the politically correct line regarding COVID and the shots.

We appreciate our friends at WND for contents in this article.

Pfizer to split into three units, separates consumer healthcare

The lawyer’s already had it figured out

July 11, 2018

FILE PHOTO: The Pfizer logo is seen at their world headquarters in New York April 28, 2014. REUTERS/Andrew Kelly/File Photo

(Reuters) – Pfizer Inc said on Wednesday it would reorganize into three units, separating its consumer healthcare business that the U.S. drugmaker has been trying to sell since last year.

The news comes a day after the company decided to defer drug price increases for no more than six months, following criticism from U.S. President Donald Trump for raising list prices of some medicines.

The units would be Innovative Medicines, Established Medicines and Consumer Healthcare. The company is currently split into two units – Innovative Medicines, which includes the consumer business, and Essential Health.

“This design gives us a sharper focus on diverse patients in diverse markets,” Albert Bourla, chief operating officer said.

The Innovative Medicines business will now also include biosimilars and a new hospital business unit, and together with the Consumer Healthcare business, will account for about three-quarters of the company’s revenue. Pfizer’s 2017 annual revenue was $52.55 billion.

Pfizer said it would still evaluate options for its consumer healthcare business and expects to make a decision in 2018.

The company said in October last year that it was considering the sale or spin-off of the consumer healthcare business, which is worth about $15 billion. In May, Pfizer said that it had not received an acceptable offer.

The business consists of products ranging from Advil to lip balms.

The Established Medicines unit would include the majority of the company’s off-patent brands, including Viagra and neurological disease treatment Lyrica as well as some generic drugs.

The changes would be effective at the start of fiscal 2019.

Pfizer shares were flat at $37.40 in premarket trading.

(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur and Sweta Singh)